Isotopia Molecular Imaging

Executive Summary

Isotopia Molecular Imaging is an Israeli radiopharmaceutical company specializing in the design, manufacture, and distribution of GMP-grade diagnostic and therapeutic isotopes, including Lu-177, Tb-161, and Ga-68 kits. Founded in 2007 and headquartered in Modiin, the company operates a commercial-stage, private business with 200-500 employees. Its core expertise lies in high-volume aseptic production and contract manufacturing (CMO) services, enabling it to supply theranostic solutions for oncology imaging and treatment. Isotopia is well-positioned in the rapidly growing radiopharmaceutical market, driven by the increasing adoption of theranostics and the demand for targeted radionuclide therapies. The company's focus on Lu-177 and emerging isotopes like Tb-161 addresses key needs in prostate cancer, neuroendocrine tumors, and other malignancies, with a strong emphasis on quality and regulatory compliance. Isotopia's competitive advantage stems from its integrated production capabilities and established supply chain, allowing it to serve both diagnostic and therapeutic segments. The company benefits from long-term trends such as aging populations, rising cancer incidence, and expanding use of nuclear medicine. As a private entity, it maintains flexibility in pursuing strategic partnerships and capacity expansions. Key growth drivers include scaling up Tb-161 production, expanding Ga-68 kit approvals globally, and securing collaborations with pharmaceutical companies to co-develop theranostic pipelines. While the radiopharmaceutical space is competitive, Isotopia's technical expertise and commercial track record position it for sustained growth.

Upcoming Catalysts (preview)

• Q4 2026Scale-up of Tb-161 production capacity to meet clinical demand80% success
• Q2 2027Regulatory approval for Ga-68 kit in major markets (e.g., FDA/EMA)70% success
• Q1 2027Strategic collaboration with a top-10 pharma for theranostic pipeline development60% success